Mairs RJ - Search Results

1

A transfectant mosaic xenograft model for evaluation of targeted radiotherapy in combination with gene therapy in vivo.

Mairs RJ, Ross SC, McCluskey AG, Boyd M. Mairs RJ, et al. J Nucl Med. 2007 Sep;48(9):1519-26. doi: 10.2967/jnumed.107.042226. Epub 2007 Aug 17. J Nucl Med. 2007. PMID: 17704246 Free article.

2

An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation-mediated bystander effects.

Boyd M, Mairs RJ, Keith WN, Ross SC, Welsh P, Akabani G, Owens J, Vaidyanathan G, Carruthers R, Dorrens J, Zalutsky MR. Boyd M, et al. Among authors: mairs rj. J Gene Med. 2004 Aug;6(8):937-47. doi: 10.1002/jgm.578. J Gene Med. 2004. PMID: 15293352

3

Application of targeted radiotherapy/gene therapy to bladder cancer cell lines.

Fullerton NE, Mairs RJ, Kirk D, Keith WN, Carruthers R, McCluskey AG, Brown M, Wilson L, Boyd M. Fullerton NE, et al. Among authors: mairs rj. Eur Urol. 2005 Feb;47(2):250-6. doi: 10.1016/j.eururo.2004.09.009. Eur Urol. 2005. PMID: 15661422

4

[131I]MIBG and topotecan: a rationale for combination therapy for neuroblastoma.

McCluskey AG, Boyd M, Gaze MN, Mairs RJ. McCluskey AG, et al. Among authors: mairs rj. Cancer Lett. 2005 Oct 18;228(1-2):221-7. doi: 10.1016/j.canlet.2004.11.062. Cancer Lett. 2005. PMID: 15935554 Review.

5

Gene manipulation to enhance MIBG-targeted radionuclide therapy.

Mairs RJ, Fullerton NE, Cosimo E, Boyd M. Mairs RJ, et al. Nucl Med Biol. 2005 Oct;32(7):749-53. doi: 10.1016/j.nucmedbio.2005.03.011. Nucl Med Biol. 2005. PMID: 16243651 Review.

6

[131I]meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter.

McCluskey AG, Boyd M, Ross SC, Cosimo E, Clark AM, Angerson WJ, Gaze MN, Mairs RJ. McCluskey AG, et al. Among authors: mairs rj. Clin Cancer Res. 2005 Nov 1;11(21):7929-37. doi: 10.1158/1078-0432.CCR-05-0982. Clin Cancer Res. 2005. PMID: 16278418

7

Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionuclides.

Boyd M, Ross SC, Dorrens J, Fullerton NE, Tan KW, Zalutsky MR, Mairs RJ. Boyd M, et al. Among authors: mairs rj. J Nucl Med. 2006 Jun;47(6):1007-15. J Nucl Med. 2006. PMID: 16741311 Free article.

8

Comparison of radiohaloanalogues of meta-iodobenzylguanidine (MIBG) for a combined gene- and targeted radiotherapy approach to bladder carcinoma.

Fullerton NE, Boyd M, Ross SC, Pimlott SL, Babich J, Kirk D, Zalutsky MR, Mairs RJ. Fullerton NE, et al. Among authors: mairs rj. Med Chem. 2005 Nov;1(6):611-8. doi: 10.2174/157340605774598090. Med Chem. 2005. PMID: 16787344

9

Radiation quality-dependent bystander effects elicited by targeted radionuclides.

Boyd M, Sorensen A, McCluskey AG, Mairs RJ. Boyd M, et al. Among authors: mairs rj. J Pharm Pharmacol. 2008 Aug;60(8):951-8. doi: 10.1211/jpp.60.8.0002. J Pharm Pharmacol. 2008. PMID: 18644188 Review.

10

In vivo evaluation of a cancer therapy strategy combining HSV1716-mediated oncolysis with gene transfer and targeted radiotherapy.

Sorensen A, Mairs RJ, Braidwood L, Joyce C, Conner J, Pimlott S, Brown M, Boyd M. Sorensen A, et al. Among authors: mairs rj. J Nucl Med. 2012 Apr;53(4):647-54. doi: 10.2967/jnumed.111.090886. Epub 2012 Mar 13. J Nucl Med. 2012. PMID: 22414636 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

94 results

Search Page

Filters